Key advances and application prospects of PROTAC technologies in the next 5 years.
作者信息
Qin Shuanglin, Xiao Xiaohe
机构信息
Senior Department of Hepatology, China Military Institute of Chinese Materia, The Fifth Medical Center of PLA General Hospital, Beijing, P.R. China.
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Research Center for Precision Medication of Chinese Medicine, FuRong Laboratory, Hunan University of Chinese Medicine, Changsha, P.R. China.
出版信息
Future Med Chem. 2025 May;17(9):987-989. doi: 10.1080/17568919.2025.2498875. Epub 2025 May 2.
Abstract
摘要
相似文献
1
Key advances and application prospects of PROTAC technologies in the next 5 years.PROTAC技术在未来5年的关键进展与应用前景。
Future Med Chem. 2025 May;17(9):987-989. doi: 10.1080/17568919.2025.2498875. Epub 2025 May 2.
2
Optimization of the PROTAC linker region of the proteasome substrate receptor hRpn13 rationalized by structural modeling with molecular dynamics.通过分子动力学结构建模对蛋白酶体底物受体hRpn13的PROTAC接头区域进行优化
J Biol Chem. 2025 Apr 19;301(6):108520. doi: 10.1016/j.jbc.2025.108520.
3
PROTAC 2.0: Expanding the frontiers of targeted protein degradation.PROTAC 2.0：拓展靶向蛋白质降解的前沿领域。
Drug Discov Today. 2025 Jun;30(6):104376. doi: 10.1016/j.drudis.2025.104376. Epub 2025 May 8.
4
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.PROTAC 降解的细胞周期蛋白依赖性激酶在乳腺癌治疗中的研究进展
Breast Cancer (Dove Med Press). 2025 Jun 13;17:511-521. doi: 10.2147/BCTT.S527906. eCollection 2025.
5
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
6
Clozapine as an E3 Ligand for PROTAC Technology.氯氮平作为用于PROTAC技术的E3连接酶配体
ACS Med Chem Lett. 2025 Jan 8;16(2):258-262. doi: 10.1021/acsmedchemlett.4c00500. eCollection 2025 Feb 13.
7
Unraveling chain specific ubiquitination in cells using tandem ubiquitin binding entities.利用串联泛素结合实体解析细胞中特定链的泛素化
Sci Rep. 2025 Jul 2;15(1):22961. doi: 10.1038/s41598-025-07242-9.
8
Advances in DNA-based proteolysis-targeting chimeras technology: Novel strategies for targeting previously undruggable proteins in cancer therapy.基于DNA的蛋白酶靶向嵌合体技术进展：癌症治疗中靶向既往不可成药蛋白的新策略
Bioorg Med Chem. 2025 Jun 28;129:118297. doi: 10.1016/j.bmc.2025.118297.
9
DeepPSA: A Geometric Deep Learning Model for PROTAC Synthetic Accessibility Prediction.深度前列腺特异性抗原（DeepPSA）：一种用于PROTAC合成可及性预测的几何深度学习模型。
J Chem Inf Model. 2025 Jul 14;65(13):6861-6873. doi: 10.1021/acs.jcim.5c00366. Epub 2025 Jun 25.
10
PROTACs coupled with oligonucleotides to tackle the undruggable.与寡核苷酸偶联的PROTAC用于攻克不可成药靶点。
Bioanalysis. 2025 Feb;17(4):261-276. doi: 10.1080/17576180.2025.2459528. Epub 2025 Feb 3.
引用本文的文献
1
Effects of Sweating and Drying Processes on Chemical Components, Antioxidant Activity, and Anti-Acute Liver Injury Mechanisms of Based on the Spectrum-Effect Relationship.基于谱效关系的发汗与干燥过程对[具体药物名称未给出]化学成分、抗氧化活性及抗急性肝损伤机制的影响
Int J Mol Sci. 2025 Sep 5;26(17):8686. doi: 10.3390/ijms26178686.
2
Isolation, Characterization, and Anticancer Evaluation of Alkaloids from (Rubiaceae).茜草科植物生物碱的分离、表征及抗癌评估
ACS Omega. 2025 Aug 4;10(32):35719-35737. doi: 10.1021/acsomega.5c02401. eCollection 2025 Aug 19.
3
Cinobufagin Inhibits Invasion and Migration of Non-Small Cell Lung Cancer via Regulating Glucose Metabolism Reprogramming in Tumor-Associated Macrophages.华蟾毒精通过调节肿瘤相关巨噬细胞中的糖代谢重编程抑制非小细胞肺癌的侵袭和迁移。
Drug Des Devel Ther. 2025 Aug 2;19:6647-6664. doi: 10.2147/DDDT.S531190. eCollection 2025.
4
Time-Dependent Impact of Betulin and Its Derivatives on IL-8 Expression in Colorectal Cancer Cells with Molecular Docking Studies.桦木醇及其衍生物对结肠癌细胞中白细胞介素-8表达的时间依赖性影响及分子对接研究
Int J Mol Sci. 2025 Jun 27;26(13):6186. doi: 10.3390/ijms26136186.
5
Nephrotoxicity and Modern Volatile Anesthetics: A Narrative Review.肾毒性与现代挥发性麻醉剂：一篇叙述性综述
Toxics. 2025 Jun 19;13(6):514. doi: 10.3390/toxics13060514.
本文引用的文献
1
PROTACs coupled with oligonucleotides to tackle the undruggable.与寡核苷酸偶联的PROTAC用于攻克不可成药靶点。
Bioanalysis. 2025 Feb;17(4):261-276. doi: 10.1080/17576180.2025.2459528. Epub 2025 Feb 3.
2
PROTACs in the treatment of viral diseases.用于治疗病毒性疾病的蛋白水解靶向嵌合体（PROTACs）
Future Med Chem. 2025 Feb;17(3):267-269. doi: 10.1080/17568919.2025.2453418. Epub 2025 Jan 15.
3
Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC).基于独特氨基酸的 PROTACs 靶向降解非小细胞肺癌（NSCLC）中的致癌激酶。
J Med Chem. 2024 Aug 22;67(16):13666-13680. doi: 10.1021/acs.jmedchem.4c00208. Epub 2024 Aug 8.
4
PROTAC technology: From drug development to probe technology for target deconvolution.PROTAC 技术：从药物研发到靶标解析探针技术。
Eur J Med Chem. 2024 Oct 5;276:116725. doi: 10.1016/j.ejmech.2024.116725. Epub 2024 Jul 30.
5
Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism.通过靶向蛋白降解机制实现对蚊媒黄病毒的广谱活性。
Nat Commun. 2024 Jun 19;15(1):5179. doi: 10.1038/s41467-024-49161-9.
6
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.口服雌激素受体 PROTAC 降解剂（ARV-471）在 ER+ 乳腺癌模型中作为单药治疗以及与 CDK4/6 或 PI3K/mTOR 通路抑制剂联合使用具有高度疗效。
Clin Cancer Res. 2024 Aug 15;30(16):3549-3563. doi: 10.1158/1078-0432.CCR-23-3465.
7
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.新型冠状病毒主要蛋白酶的首创蛋白降解靶向嵌合体（PROTAC）降解剂的发现。
J Med Chem. 2024 Apr 25;67(8):6495-6507. doi: 10.1021/acs.jmedchem.3c02416. Epub 2024 Apr 12.
8
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.用于细胞选择性和靶向降解活化 STAT3 的寡聚 PROTAC 策略。
Mol Ther Nucleic Acids. 2024 Feb 5;35(1):102137. doi: 10.1016/j.omtn.2024.102137. eCollection 2024 Mar 12.
9
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates.发现用于神经退行性疾病相关聚集物的有效双 PROTAC 降解剂。
J Med Chem. 2024 Mar 14;67(5):3448-3466. doi: 10.1021/acs.jmedchem.3c01719. Epub 2024 Feb 14.
10
Nano-PROTACs: state of the art and perspectives.纳米-PROTACs：现状与展望。
Nanoscale. 2024 Feb 29;16(9):4378-4391. doi: 10.1039/d3nr06059d.
Zotero 插件